Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
Enovis CORP reported the fourth quarter ended December 31, 2022 results: revenue $409 million, net income net loss from continuing operations of $55 million, or $0.71 per diluted share, EPS $0.72.
- Period
- the fourth quarter ended December 31, 2022
- Revenue
- $409 million
- Net income
- net loss from continuing operations of $55 million, or $0.71 per diluted share
- EPS
- $0.72
- Result
- reported results
Exact text from the filing
• Completed first year as independent Med Tech growth company with sales growth of 10%, organic growth of 6% and EBITDA margin expansion • Grew fourth quarter sales 2% to $409 million, with 5% organic growth over the prior year quarter, and double-digit growth performance in its Reconstructive segment • Reported a fourth quarter net loss from continuing
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
Enovis CORP reported the 2022 fiscal year results: revenue $1.6 billion, net income net loss from continuing operations of $38 million, or $0.25 per diluted share, EPS $2.27. Guidance initiated.
- Period
- the 2022 fiscal year
- Revenue
- $1.6 billion
- Net income
- net loss from continuing operations of $38 million, or $0.25 per diluted share
- EPS
- $2.27
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
segment grew 12%, and 14% on an organic basis, and its Prevention and Recovery segment declined 2% with 1% organic growth. For the 2022 fiscal year, net sales grew 10% to $1.6 billion, with organic growth of 6%. Enovis also reported a fourth quarter operating loss of $28 million or 6.9% of sales, and adjusted EBITDA of $75 million, or 18.3% of sales, an
View on SEC.gov